By Fineline Cube 
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has secured an investigational new drug (IND) approval from the US FDA for its βKlotho monoclonal antibody (mAb) JMT202. The drug is designed to reduce triglyceride (TG) levels in patients with hypertriglyceridemia and is currently undergoing clinical trials in China, following clearance obtained in May of last year.
Mechanism of Action and Potential Indications
JMT202 is an FGFR1c/βKlotho receptor agonist that binds to βKlotho protein, specifically activating the FGFR1c/βKlotho receptor complex to simulate its natural ligand, the FGF21 protein. This action helps regulate glucose and lipid metabolism. JMT202 has the potential to treat a range of metabolic diseases, including dyslipidemia, nonalcoholic steatohepatitis (NASH), type 2 diabetes, obesity, and other related conditions. It also holds promise for combination use with other targeted drugs, such as GLP-1 agonists, that regulate glucose and lipid metabolism.
Preclinical Findings
Preclinical studies have demonstrated that JMT202 has a favorable safety profile and a relatively long dosing interval. The molecule has shown significant potential to reduce triglycerides and exhibit lipid-lowering effects, making it a valuable candidate for further clinical development.-Fineline Info & Tech